Venrock Associates VII, L.P. - 17 Jun 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CYT	Series B Convertible Preferred Stock							17 Jun 2021	Common Stock	2,933,583		By Funds	F1, F2, F3
holding	CYT	Series C Convertible Preferred Stock							17 Jun 2021	Common Stock	325,442		By Funds	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Issuer's common stock shown in column 3 and has no expiration date. The Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F2	Consists of 2,709,164 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock held by Venrock Associates VII, L.P. ("VA VII") and 224,419 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock held by Venrock Partners VII, L.P. ("VP VII").
F3	Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein.
F4	Consists of 300,546 shares of common stock issuable upon conversion of Series C Convertible Preferred Stock held by VA VII and 24,896 shares of common stock issuable upon conversion of Series C Convertible Preferred Stock held by VP VII.